BOSTON ( TheStreet) -- The American Society of Clinical Oncology (ASCO) annual meeting, held this year June 4-8, brings together cancer drug researchers from all over the world to discuss and present new clinical data aimed at treating -- and maybe one day curing -- cancer.

The ASCO annual meeting also attracts investors in almost equal numbers because treating cancer is big business. Wall Street pays close attention because the ASCO meeting moves biotech and drug stocks, often well before the ASCO confab even gets started.

Toxic Supplements (Forbes)

I've assembled a list of biotech and drug stocks that will be presenting new clinical data at this year's ASCO meeting. The list isn't exhaustive, but covers stocks that will likely receive the most investor attention at the meeting. (And as I point out, many of these stocks have already started to run up as the ASCO meeting approaches.)

ASCO has already posted online the research abstract titles for this year's meeting. On May 20 at 6 p.m. EDT, ASCO will post the content of those abstracts, which will contain more information about the data to be presented.

Celldex Therapeutics ( CLDX)

Drug: CDX-110 (PF-04948568)

Abstract No.2014

Indication: Glioblastoma (brain tumor)

Clinical Trial: Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide in patients with glioblastoma (GBM).

Presentation Time: Saturday, June 5. Poster session.

Notes: Celldex's CDX-110, partnered with Pfizer, is engineered to activate a patient's immune system to fight cancer. Interest in so-called cancer "vaccines" is increasing as Dendreon ( DNDN) awaits FDA approval of its prostate cancer immunotherapy Provenge. Celldex shares are running strong into the ASCO meeting, up 60% since February.

ArQule ( ARQL)

Drug:ARQ 197

Abstract No.LBA7502

Indication: Non-small cell lung cancer

Clinical Trial: Results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-negative patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Presentation Time: Saturday, June 5. Oral session.

Notes: Arqule announced top-line results from this phase II study of ARQ 197 at the end of March.

Delcath Systems ( DCTH)

Drug: Percutaneous Hepatic Perfusion

Abstract No. LBA8512

Indication: Liver metastases from melanoma

Clinical Trial: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma.

Presentation Time: Saturday, June 5. Oral session.

Notes: Investors will get the first detailed look at data from the positive phase III study announced last week.

Pharmacyclics ( PCYC)

Drug: PCI-32765

Abstract No. 8012

Indication: non-Hodgkin's lymphoma

Clinical Trial: Btk inhibitor PCI-32765 monotherapy induces objective responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a phase I study.

Presentation Time: Saturday, June 5. Oral session.

Notes: Since December, Pharmacyclics shares have gone from $2 to $7 as the company puts a history of drug development failures behind it and builds a new research pipeline.

Bristol-Myers Squibb ( BMY)

Drug: ipilimumab

Abstract No. 4

Indication: melanoma

Clinical Trial: A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Presentation Time:Sunday, June 6. ASCO Plenary Session.

Notes:Bristol gained full ownership of ipilimumab when it acquired Medarex in 2009.

Celgene ( CELG)

Drug: Revlimid

Abstract No. 8017

Indication: Multiple myeloma

Clinical Trial: Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma: CALGB 100104.

Presentation Time: Sunday, June 6. Oral session.

Notes: A separate and equally important study of Revlimid maintenance after stem cell transplant for myeloma will be presented during the same session.

Pfizer ( PFE)

Drug: PF-02341066

Abstract No. 3

Indication: non-small cell lung cancer

Clinical Trial: Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer.

Presentation Time: Sunday, June 6. ASCO Plenary Session.

Notes: Pfizer gets a primetime slot at ASCO to highlight its research efforts into personalized cancer drugs.

Nektar Therapeutics ( NKTR)

Drug: NKTR-102

Abstract No. 5013

Indication: ovarian cancer

Clinical Trial: Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Presentation Time: Sunday, June 6. Oral session.

Notes: Nektar announced top-line results from this study in early March.

Roche/Genentech

Drug: Avastin

Abstract No. LBA1

Indication: Ovarian cancer

Clinical Trial: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Presentation Time: Sunday, June 6. ASCO Plenary Session.

Notes: Once again, Genentech and Avastin claim a covered spot on the podium during ASCO's plenary session.

Ziopharm Oncology ( ZIOP)

Drug: palifosfamide

Abstract No. 10004

Indication: Sarcoma

Clinical Trial: A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO).

Presentation Time: Monday, June 7. Oral session.

Notes: Ziopharm is in the planning stages for a pivotal phase III study of palifosfamide in soft tissue sarcoma, expected to begin later this year.

Sunesis Pharmaceuticals ( SNSS)

Drug: Voreloxin

Abstract No. 5002

Indication: ovarian cancer

Clinical Trial:Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer.

Presentation Time: Monday, June 7. Oral session.

Notes: Sunesis will also be presenting final phase II data from a study of voreloxin in patients with acute myeloid leukemia.

Curis ( CRIS)

Drug: GDC-0449

Abstract No. 3530

Indication: colorectal cancer

Clinical Trial: Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 vs. placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

Presentation Time: Tuesday, June 8. Poster session.

Notes:GDC-0449 is partnered with Roche/Genentech.

Keryx Pharmaceuticals ( KERX)

Drug: perifosine

Abstract No. 3531

Indication: colorectal cancer

Clinical Trial: Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients with second- or third-line metastatic colorectal cancer.

Presentation Time: Tuesday, June 8. Poster session.

Notes:Keryx has already started a phase III study of perifosine in colorectal cancer.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Danica Patrick's Final Race at 2018 Indianapolis 500: What She Thinks About Cars

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

Why The FANG Stocks' Dominance May Not Be So Bad For The Market

At End of May, Investors Signalling They May Stay Away

At End of May, Investors Signalling They May Stay Away

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever